<DOC>
	<DOCNO>NCT01523639</DOCNO>
	<brief_summary>This multicenter randomize , placebo-controlled phase II study enroll 132 first-line palliative treat subject metastatic KRAS wild type CRC . Subjects histologically confirm , KRAS wild-type CRC without previous chemo-therapy metastatic disease screen study . Approximately 10 site Austria participate study . Subjects randomize ratio 1:1 two group .</brief_summary>
	<brief_title>A Randomized , Placebo-controlled , Double-blind Phase II Study Evaluating Glucophage Can Avoid Liver Injury Due Chemotherapy Associated Steatosis</brief_title>
	<detailed_description>This multicenter randomize , placebo-controlled phase II study enroll 132 first-line palliative treat subject metastatic KRAS wild type CRC . Wild-type KRAS require study entry . Further target-related parameter , base current scientific knowledge may assess . Subjects randomize Arm A Arm B Arm A : FOLFIRI combination cetuximab metformin Arm B : FOLFIRI combination cetuximab placebo A liver biopsy hepatic metastasis normal liver tissue plan first cycle end treatment ; regard primary study objective , subject evaluable . Both efficacy safety data collect . The investigator assess response treatment every 8 week base image . Following permanent treatment cessation , subject followed-up survival . One interim analysis futility ( 54 evaluable patient ) addition two safety analysis evaluation report adverse event two treatment group perform two different timepoints ( 20 evaluable patients/54 evaluable patient ) .</detailed_description>
	<mesh_term>Colorectal Neoplasms</mesh_term>
	<mesh_term>Fatty Liver</mesh_term>
	<mesh_term>Metformin</mesh_term>
	<mesh_term>Cetuximab</mesh_term>
	<criteria>Signed write informed consent Male female &gt; = 18 year age Diagnosis histologically confirm , KRAS `` wildtype '' adenocarcinoma colon rectum Nonresectable metastatic colorectal carcinoma Either presence least one liver lesion measurable unidimensionally CT scan MRI least one resectable liver metastasis nonresectable extrahepatic disease ( assess within 3 week prior randomisation ) Subjects schedule receive cetuximab FOLFIRI ECOG performance status 0 1 study entry Leukocytes &gt; = 3.0 x 10^9/L neutrophil &gt; = 1.5 x 10^9/L , platelet &gt; = 100 x 10^9/L , hemoglobin &gt; = 8 g/dL Bilirubin &lt; = 1.5 x ULN ASAT ALAT &lt; = 5 x ULN Brain metastasis ( suspect , brain scan indicate ) Previous chemotherapy currently exist metastatic disease Known newly diagnose diabetes Patients ACS within last three month Stage 3 4 heart failure define accord NYHA criterion Uncontrolled angina Contraindications metformin ( renal impairment [ eGFR &lt; 45 mL/min/1.73m^2 ] , know hypersensitivity metformin , acute illness [ dehydration , severe infection , shock , acute cardiac failure ] ) , suspect tissue hypoxia Surgery ( excl . diagnostic biopsy , central venous catheter ) irradiation within 2 week prior study entry define give write informed consent Concurrent chronic systemic immune therapy , chemotherapy , hormone therapy indicate study protocol Administration investigational agent ( ) within 4 week prior study entry , Previous exposure EGFRpathway target therapy Acute subacute intestinal occlusion history inflammatory bowel disease Known grade 3 4 allergic reaction component treatment Any concurrent malignancy nonmelanoma skin cancer , carcinoma situ cervix . ( Subjects previous malignancy without evidence disease &gt; = 5 year allow enter trial ) Pregnancy lactation Inadequate contraception ( male female patient ) childbearing procreative potential Known drug abuse/ alcohol abuse Legal incapacity limit contractual capacity Medical psychological condition opinion investigator would permit patient complete study sign meaningful inform consent</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2014</verification_date>
	<keyword>liver injury</keyword>
	<keyword>steatosis</keyword>
	<keyword>KRAS-Wild-Type</keyword>
	<keyword>metastatic colorectal cancer</keyword>
	<keyword>metformin</keyword>
	<keyword>placebo</keyword>
	<keyword>chemotherapy</keyword>
</DOC>